Journal of Oncology / 2021 / Article / Tab 3

Research Article

Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection

Table 3

Independent prognostic factors for OS.

CharacteristicsHeadBody/Tail
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR95%CIHR95%HR95%CIHR95%CI

Age≤60 yearsReference0.126NIReference0.544NI
>60 years1.3880.912–2.1111.3360.524–3.409
GenderFemaleReference0.271NIReference0.303NI
Male0.7900.519–1.2021.6700.630–4.428
WBC≤10Reference0.001Reference0.066Reference0.648NI
>102.7621.553–4.9090.4000.151–1.0610.0460.000–1.864
NLR≤3.32Reference0.280NIReference0.941NI
>3.321.2620.827–1.9250.9450.210–4.241
dNLR≤3.32Reference0.457NIReference0.326NI
>3.321.1930.749–1.9000.6300.250–1.586
PLR≤98.13Reference0.274NIReference0.944NI
>98.131.6570.671–4.0921.0340.409–2.613
PNI0Reference0.588NIReference0.237NI
11.1470.699–1.8813.3940.449–25.680
SII≤1000Reference0.838NIReference0.367NI
>10001.0470.677–1.6180.0410.000–43.052
mGPS0ReferenceNIReferenceNI
10.9640.524–1.7750.9070.5790.071–4.7390.610
21.3530.681–2.6850.3381.1870.118–11.9740.884
PI0ReferenceReference0.564ReferenceNI
10.3930.204–0.7580.0051.5400.355–6.6841.8410.734–3.1230.950
20.4600.229–0.9260.0300.9570.239–3.8260.9511.4520.665–2.2130.945
ALB (g/L)≤35Reference0.838NIReference0.688NI
>350.9470.563–1.5940.6520.081–5.244
CRP (ng/L)≤3Reference0.315NIReference0.253NI
>31.2440.813–1.9041.9640.618–6.243
CA19-9 (U/ml)≤35Reference0.019Reference0.340Reference0.063NI
>352.0261.123–3.6561.3740.715–2.6384.2640.813–7.831
CEA (ng/ml)≤5Reference0.103NIReference0.153NI
>51.4480.928–2.2611.9510.781–4.873
HBV infectionAbsenceReference0.713NIReference0.573NI
Presence1.1860.479–2.9351.8010.232–13.955
ChemotherapyNoReference0.240NIReference0.886NI
Yes0.7760.509–1.1850.9360.376–2.325
HemorrhageAbsenceReference0.954NIReference0.402NI
Presence1.0430.255–4.2560.0380–80.925
Pancreatic fistulaAbsenceReference0.351NIReference0.059NI
Presence1.2480.784–1.9861.1380.018–1.082
Biliary fistulaAbsenceReference0.702NIReference0.330NI
Presence1.1090.652–1.8870.5270.145–1.914
Abdominal infectionAbsenceReference0.143NIReference0.887NI
Presence1.5530.861–2.8011.1600.151–8.904
Time period to recurrence (month)>24ReferenceReferenceReference
≤65.1652.358–11.316<0.00118.3376.998–48.047<0.00110.7411.340–86.0930.02519.4529.010–53.421<0.001
6–124.2121.871–9.4840.00113.9945.341–36.626<0.0017.1930.756–68.4480.0865.3323.761–22.191<0.001
12–243.0721.268–7.4380.0134.8421.814–12.9230.00211.7931.140–12.9980.0381.3911.121–3.3210.011
LN16AbsenceReferenceLAReference0.046ReferenceLAReference0.908
Presence2.5061.017–6.1722.5310.932–4.663
Tumor differentiationWellReferenceLAReferenceReferenceLAReference
Moderate2.1311.252–3.6410.0060.0110.000–0.8710.043
Poor3.5221.446–5.3120.0027.0471.123–4.1960.037
Imaging tumor size (cm)≤2ReferenceLAReferenceReferenceLAReference
2–40.9150.417–2.0070.8240.2090.042–2.1240.985
>41.0010.492–2.0350.9990.1800.015–2.1800.178
Local progressionAbsenceReferenceLAReference<0.001ReferenceLAReference<0.001
Presence7.0913.645–13.8990.0010–0.051
Liver-only metastasisAbsenceReferenceLAReference<0.001ReferenceLAReference0.001
Presence11.4905.351–24.3970.0120.001–0.178
Lung-only metastasisAbsenceReferenceLAReference0.001ReferenceLAReference0.287
Presence4.7801.871–12.3510.2450.018–3.268
Local + distant metastasisAbsenceReferenceLAReference0.031ReferenceLAReference0.917
Presence4.2141.142–15.5500.3120.087–3.042

NI, not included; LA, included in LASSO analysis. Abbreviations as in Table 1.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.